Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LetiCaderm
- Development stage
- Unknown
- Lead developer
- Leti
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LetiCaderm is a topical veterinary skincare line developed by LETI Pharma (Leti) as part of their LETI+Derma dermatological product range for companion animals. It is specifically designed to manage atopic skin conditions in dogs and cats by addressing skin barrier dysfunction and lipid metabolism disorders. The formulation contains a combination of scientifically selected active ingredients: polidocanol, which acts as an antipruritic agent; myristyl phospho-malate, a sphingosine-1-phosphate (S1P) analogue that stimulates the synthesis of filaggrin and ceramides; essential fatty acids (linoleic and linolenic acid) that serve as precursors for ceramide 1; and pomegranate polyphenols for antioxidant and antimicrobial support. LetiCaderm is used as an over-the-counter (OTC) product to soothe pruritus, restore the epidermal barrier, protect against irritants, and control pathogen overgrowth in animals with atopic dermatitis.
- Brand names
- LetiCaderm
- Other names
- LETI+Derma line
02
Targets
EDG1 (Sphingosine-1-phosphate receptors)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on LetiCaderm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LetiCaderm.